Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy
ConditionBreast Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorPeking University Cancer Hospital & Institute
About this trial
To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value in breast patients treated with ADC therapy
Eligibility criteria
Qualifiers
Aged ≥18 years old; ECOG 0 or 1;
Patients with HER2 positive or low tumors;
Receives neoadjuvant therapy
Has adequate cardiac, bone marrow, renal, hepatic and blood clotting functions;
Disqualifiers
Significant hepatic or renal dysfunction;
Is pregnant or ready to pregnant;
Cannot keep their states for half an hour;
Refused to join the clinical research;
Trial design
Treatments tested in this trial
- HER2 expression of PET imaging
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Peking University Cancer Hospital & Institute
Lead sponsor
The Affiliated Hospital of Qingdao University
Collaborator
North Sichuan Medical College
Collaborator
Source ClinicalTrials.gov